MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced six-month ...

Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).

MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion ... which could lead to potential peak sales of approximately $100 million per 1,000 patients treated.

When Peak Design CEO Peter Dering identified a backpack linked to Luigi Mangione, the suspected shooter of UnitedHealthcare CEO Brian Thompson, he contacted police in a move he called instinctive. But ...

In an interview with The New York Times, Peak Design CEO Peter Dering said multiple people alerted him via text that the alleged shooter depicted in surveillance images released by police appeared ...

As the year draws to a close, skywatchers have an opportunity to witness the annual Ursid meteor shower, which is expected to peak this weekend. The Ursids mark the second week of back-to-back ...

The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...

A person uses Afrezza inhaled insulin powder. [Image courtesy of MannKind] MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

The insulin called Afrezza is created and manufactured by MannKind Corporation, and is used to improve glycemic control in adults with diabetes mellitus.“Afrezza is a rapid-acting insulin ...